Asymchem Laboratories (Tianjin) Co., Ltd. (002821)

Equity Research Report | Sector: Pharmaceuticals & Biotech / Medical R&D Outsourcing (CXO/CDMO) | Report Date: September 13, 2026 | As of the close on September 11, 2026; some quote pages have delays, rounding differences, and discrepancies in statistical methodology

This report is automatically compiled and generated by AI based on public information and is for reference only. It does not constitute investment advice.

1. Core Summary

Asymchem achieved operating revenue of RMB 3.607 billion in H1 2026, up 13.13% year-on-year, but net profit attributable to shareholders was RMB 520 million, down 15.71% year-on-year, primarily affected by exchange losses expanding to approximately RMB 200 million; adjusted net profit was RMB 753 million, up 12.90% year-on-year, and net cash flow from operating activities was RMB 822 million, up 17.18% year-on-year. Therefore, the company currently exhibits a characteristic of revenue and operating profitability maintaining growth, while book net profit attributable to shareholders is disturbed by exchange rate fluctuations.

Growth drivers are shifting from traditional small-molecule CDMO to emerging businesses. In H1 2026, emerging business revenue was RMB 1.304 billion, up 72.49% year-on-year, with its share rising to 36.16%, of which chemical macromolecule and biological macromolecule revenue grew 94.14% and 122.82% respectively; during the same period, small-molecule CDMO revenue was RMB 2.297 billion, down 5.44% year-on-year, but gross margin improved to 47.83%. As of the disclosure date, the company's backlog was USD 1.673 billion, up 53.77% year-on-year, with new signed orders up 54.59% year-on-year, and the company's full-year 2026 revenue guidance is year-on-year growth of 19%–22%.

The company has a globalized customer base and a technology-driven CDMO positioning, with overseas revenue accounting for 73.77% in 2025, small-molecule CDMO still accounting for the majority of revenue, more than 5,200 R&D and analytical personnel, and R&D investment of RMB 593 million in 2025. At the same time, although emerging businesses are growing rapidly, their 2025 gross margin was 30.12%, lower than the 46.83% of small-molecule CDMO, and subsequent profitability improvement still depends on whether business structure upgrading, capacity ramp-up, and process cost reduction can be continuously realized.

As of September 11, 2026, the company's stock price closed at RMB 164.13, with a dynamic P/E ratio of approximately 56.6–56.9x, about 17.94% below the 52-week high of RMB 200. Technically, the stock price is below MA10, MA20, and the Bollinger middle band, with MACD negative and RSI at approximately 41.30, indicating weak short-term momentum; stochastic RSI at approximately 10.66 suggests conditions for a technical rebound, but recent main-force capital flows have been net outflows overall, and short-term attention should still be paid to the RMB 161–164 support and RMB 169–174 resistance zones.

2. Company Overview

2.1 Basic Information

2.2 Main Business and Product Layout

• Small-molecule CDMO solutions: FY2025 revenue RMB 4.735 billion, accounting for 70.98%, gross margin 46.83% (up 3.59pct year-on-year)
• Emerging businesses (total): FY2025 revenue RMB 1.929 billion, accounting for 28.92%, gross margin 30.12% (up 57.30% year-on-year, gross margin up 8.45pct year-on-year)
• Chemical macromolecule CDMO (peptides/oligonucleotides/toxin linkers, etc.): FY2025 revenue RMB 1.028 billion, up 123.72% year-on-year
• Biological macromolecule CDMO: FY2025 revenue RMB 294 million, up 95.76% year-on-year (of which overseas project revenue accounted for 39.55%)
• Formulation CDMO: FY2025 revenue RMB 284 million, up 18.44% year-on-year
• Clinical CRO: FY2025 revenue RMB 282 million, up 26.53% year-on-year
• Synthetic biology and new technology output: revenue not separately disclosed in the annual report
• Other (supplementary): FY2025 revenue RMB 6.4 million, accounting for 0.10%
• By region: Overseas (North America + Europe + Asia excluding mainland China) RMB 4.921 billion, accounting for 73.77%; Domestic (mainland China) RMB 1.749 billion, accounting for 26.23%
• FY2025 Project Count: 59 commercial projects delivered for small molecules, 515 clinical and preclinical projects (including 70 Phase III clinical projects); 52 peptide clinical-stage projects (19 related to weight loss); 69 oligonucleotide clinical projects; 36 toxin linker clinical projects
• H1 2026 (Eastmoney main business composition methodology, pending verification against the original semi-annual report): Small-molecule CDMO RMB 2.297 billion, accounting for 63.68%, gross margin 47.83%; Emerging businesses RMB 1.304 billion, accounting for 36.16%, gross margin 32.50%; Overseas RMB 2.402 billion, accounting for 66.59%, gross margin 51.10%; Domestic RMB 1.205 billion, accounting for 33.41%, gross margin 24.67%

2.3 Industry Chain Upstream/Downstream Position and Cost-Profit Structure

Asymchem is positioned as a globally industry-leading "one-stop CDMO integrated solutions provider," technology-driven (emphasizing the "D" = Development capability that distinguishes it from traditional CMO), with the official website stating it "provides one-stop services across the full drug lifecycle to over 1,300 customers globally," covering chemical small-molecule drugs, TIDES, biologics, formulations, technology output, and synthetic biology. Its position in the industry chain is in the pharmaceutical outsourcing services segment, with upstream being fine chemicals and biological reagent inputs and labor, and downstream being global pharmaceutical companies and Biotech firms.

• The "raw materials" actually procured by the company are not mineral/metal bulk commodities, but fine chemical and biological reagent inputs: starting materials/intermediates, solvents and reagents, catalysts, enzyme preparations, packaging materials, plus energy (steam/electricity) and equipment depreciation, as well as the most core "people" (R&D + analytical personnel).
• Labor input is a key item in the cost structure: as of the end of FY2025, 10,617 employees, including 342 PhDs, 2,193 master's degree holders, 5,872 bachelor's degree holders (approximately 78.2% with bachelor's degree or above); 5,243 R&D and analytical personnel, with master's/doctoral senior researchers accounting for 38.8% of R&D personnel; FY2025 R&D investment of RMB 593 million (approximately 8.9% of revenue).
• FY2025 annual report cost total: pharmaceutical industry main business cost RMB 3.865 billion (corresponding to gross profit of RMB 2.798 billion, gross margin 41.99%).
• Supplier concentration: multiple searches this time (including "suppliers," "concentration," "top five suppliers" directions) failed to obtain the specific figure for "combined procurement share of top five suppliers" disclosed in the 2025 annual report, making it impossible to judge its procurement concentration and bargaining position—this is marked as unverified and should not be assumed.
• What can be determined: as a large-scale buyer of fine chemicals and reagents, the company is essentially a price taker for standardized solvent/reagent inputs (prices fluctuate with petrochemical/chemical raw material cycles); for custom starting materials/key intermediates, its bargaining power mainly comes from process self-development and alternative route design capabilities, rather than procurement scale.
• Indirect evidence of upstream bargaining power: FY2025 net cash flow from operating activities of RMB 1.408 billion > net profit of RMB 1.127 billion (cash flow/net profit approximately 1.25x), indicating that revenue is not driven by credit sales and inventory stuffing, the cost payment side is relatively normal, and there are no typical signs of "being squeezed by upstream."
• Downstream are global pharmaceutical companies (MNCs) and Biotech firms. FY2025 revenue structure: large pharmaceutical companies RMB 2.916 billion (43.7%), small and medium pharmaceutical companies RMB 3.755 billion (56.3%); domestic RMB 1.749 billion (26.2%), overseas RMB 4.921 billion (73.8%).
• Customer concentration (key data): FY2025 top 5 customers combined sales of RMB 2.393 billion, accounting for 35.87% of operating revenue; individual customer breakdown: Customer 1 RMB 590 million (8.85%), Customer 2 RMB 505 million (7.58%), Customer 3 RMB 469 million (7.04%), Customer 4 RMB 435 million (6.51%), Customer 5 RMB 394 million (5.91%). This data comes from a single source (Chagu.com/Gubit "002821 Business Analysis") and could not be cross-verified against the original annual report this time; please refer to the latest annual report's "Top Five Customers" section.
• Structural bargaining dynamics: the core of the CDMO industry is high customer switching costs—once a product enters late-stage clinical/commercialization, processes, impurity profiles, cGMP registration documents, and customer filing materials are deeply bound, and changing suppliers requires re-doing process validation and regulatory changes. Therefore, once a single commercial project is locked in, supplier stickiness is strong and price pressure from annual negotiations is relatively moderate.
• However, Asymchem has no pricing power over drug selling prices; its quotes are essentially "cost-plus + technology premium" service pricing; customers (especially MNC procurement departments) will still continuously pressure prices and demand cost reductions, and the company can only improve gross margin through process iteration (continuous flow, enzyme catalysis, synthetic biology) rather than price increases.
• The huge gap between domestic and overseas gross margins (H1 2026 overseas 51.10% vs. domestic 24.67%) is precisely the quantitative manifestation of this logic: overseas MNC projects have high unit prices and technology premiums, while domestic innovative drug customers are highly price-sensitive.
• Customer list (company/media disclosure): MNCs such as Merck, Pfizer, Bristol-Myers Squibb, AbbVie, Eli Lilly, as well as domestic innovative pharmaceutical companies such as Betta Pharmaceuticals, Hutchison MediPharma, Zai Lab, Fosun Pharma, and Dizal Pharma. Historically, "cooperation has been established with 15 of the world's top 20 pharmaceutical companies, and 8 of them have been served continuously for over 10 years" (this statement comes from early annual reports/prospectus materials, not the latest 2025 methodology, and is for risk control reference only).
• Indirect evidence: FY2025 net cash flow from operating activities of RMB 1.408 billion, net profit attributable to shareholders of RMB 1.133 billion (ratio approximately 1.24); FY2024 were RMB 1.254 billion / RMB 949 million respectively (ratio approximately 1.32), with cash flow covering profit for two consecutive years, a positive signal of "not being significantly owed by downstream." Asset structure: total assets at end-2025 of RMB 20.277 billion, of which non-current assets RMB 8.771 billion (accounting for 43.3%), total liabilities RMB 2.631 billion (current liabilities RMB 1.968 billion + non-current liabilities RMB 663 million), net assets attributable to shareholders RMB 17.635 billion, debt-to-asset ratio approximately 13.0%, equity-to-liability ratio (investing.com methodology) 1.95%, a "heavy asset, light liability" structure; 2025 net cash flow from investing activities of −RMB 633 million, 2024 −RMB 1.184 billion, with capacity investment being the main destination on the asset side; FY2025 period-end cash and cash equivalents balance of RMB 3.403 billion. Items not obtained: accounts receivable balance, accounts receivable turnover days, receivables/revenue or receivables/net profit ratio, prepayments and accounts payable details—these could not be obtained this time due to step limitations, so the conclusions in this section can only be based on the above indirect evidence, and cannot assert accounts receivable turnover days or aging change trends. It is recommended to supplement with the "Notes receivable and accounts receivable" notes in the 2025 annual report/H1 2026 semi-annual report.
• Customer concentration: FY2025 top 5 customers combined sales of RMB 2.393 billion, accounting for 35.87% of operating revenue (Customers 1 through 5 accounting for 8.85%, 7.58%, 7.04%, 6.51%, 5.91% respectively), data source is Chagu.com/Gubit "002821 Business Analysis," a single source that could not be cross-verified against the original annual report this time; this figure's magnitude is consistent with the disclosure direction of "large pharmaceutical company revenue of RMB 2.916 billion, single largest customer less than 10%" and is logically self-consistent. Please refer to the latest annual report's "Top Five Customers" section for specifics. Supplier concentration: the specific figure for "combined procurement share of top five suppliers" in the 2025 annual report could not be obtained, marked as unverified.

Asymchem is positioned in the upper-middle portion of the smile curve: not an upstream resource/high-margin segment, nor a downstream brand/high-margin segment, but a technology-driven CDMO in the pharmaceutical outsourcing services segment, earning "cost-plus + technology premium" service fees, with no pricing power over drug end prices and essentially a price taker for standardized solvent and reagent inputs, but with certain bargaining resilience for custom starting materials/key intermediates and commercial projects due to process self-development and high customer switching costs. The actual drivers of further gross margin improvement come from: product structure upgrading (increasing share of emerging businesses such as chemical macromolecule peptides/oligonucleotides, with 2025 emerging business revenue up 57.30% year-on-year and H1 2026 share already rising to approximately 36%), cost reduction from process iteration (continuous flow, enzyme catalysis, synthetic biology), maintaining the share of high-margin overseas MNC projects (H1 2026 overseas gross margin 51.10% vs. domestic 24.67%), and capacity/scale release, rather than relying on price increases.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

The latest complete financial report is the H1 2026 semi-annual report (reporting period 2026-06-30); Q3 2026 data has not yet been disclosed or was not retrieved as of the research time point. H1 2026 adjusted net profit RMB 753 million (+12.90%), net profit attributable to shareholders excluding non-recurring items RMB 525 million (−7.30%); the decline in net profit attributable to shareholders was mainly due to exchange losses of RMB 200 million in the reporting period (only RMB 31 million in the same period last year). H1 2026 comprehensive gross margin 42.27% (up 0.31pct year-on-year at constant currency), net margin 14.25%; net cash flow from operating activities RMB 822 million (+17.18%); debt-to-asset ratio 14.81% (2026-06-30). H1 2026 small-molecule CDMO revenue RMB 2.297 billion (accounting for 63.68%, −5.44%, gross margin 47.83%), emerging businesses revenue RMB 1.304 billion (accounting for 36.16%, +72.49%, gross margin 32.50%), of which chemical macromolecules RMB 736 million (+94.14%), biological macromolecules RMB 200 million (+122.82%), formulations RMB 178 million (+50.93%), clinical CRO RMB 143 million (+2.73%); by region, overseas RMB 2.402 billion (accounting for 66.59%), domestic RMB 1.205 billion (accounting for 33.41%, +68.95%). Backlog as of the disclosure date USD 1.673 billion (+53.77%), new signed orders +54.59%. The company's full-year 2026 guidance is revenue growth of 19%–22% year-on-year (no profit guidance). Full Year 2025 adjusted net profit RMB 1.253 billion (+56.09%), Q4 single-quarter revenue RMB 2.040 billion (+22.59%), net profit attributable to shareholders RMB 332 million (+39.27%); small molecules RMB 4.735 billion (+3.59%), emerging businesses RMB 1.929 billion (+57.30%). Per-share data (Securities Star): EPS 2026-06-30 was RMB 1.45, 2026-03-31 was RMB 0.84, 2025-12-31 was RMB 3.16, 2025-09-30 was RMB 2.18; net assets per share were RMB 49.17/49.75/48.91/48.12 respectively; ROE was 2.91%/1.71%/6.58%/4.63% respectively.

The decline in H1 2026 net profit attributable to shareholders is a book phenomenon, mainly due to expanded exchange losses (RMB 200 million vs. RMB 31 million in the same period last year). The company simultaneously disclosed adjusted net profit of +12.90%; looking only at net profit attributable to shareholders would underestimate the operating fundamentals, and the adjusted methodology should also be noted. Revenue maintained steady growth, with emerging businesses (+72.49%) being the core growth driver, while small-molecule CDMO declined slightly year-on-year (−5.44%); domestic revenue grew strongly (+68.95%). Backlog and new signed orders grew 53.77% and 54.59% year-on-year respectively, combined with the company's 2026 revenue guidance of +19%–22%, giving strong certainty for full-year growth. 2024 was a clear down year (revenue −25.8%, net profit attributable to shareholders −58.2%), providing the backdrop for the current low-base/recovery narrative. On a single-quarter basis, Q2 net profit attributable to shareholders decline (−25.69%) was larger than Q1 (−6.82%), with the exchange rate impact concentrated in Q2.

3.2 Earnings Forecast

The above 2026E/2027E/2028E data are all brokerage forecasts, not company disclosures; the company officially only provides 2026 revenue guidance of +19%–22%, with no profit guidance. Covering institutions and report dates: Kaiyuan Securities 2026-08-26, Guosen Securities 2026-09-01, Western Securities 2026-09-09, Guojin Securities 2026-08-12, Guotou Securities 2026-08-25, China Galaxy 2026-08-25, CICC 2026-08-25, Bohai Securities 2026-08-25, Huatai Securities 2026-08-24, Guosheng Securities 2026-08-15, Guotai Haitong 2026-04-10. In terms of consensus methodology, Tonghuashun iFinD (as of 2026-05-29) shows 21 institutions covering over the past six months, with 2026 net profit forecast average of RMB 1.407 billion (+24.24% year-on-year), maximum RMB 1.507 billion, minimum RMB 1.360 billion, target price average RMB 148.63 (maximum 160, minimum 136.15); this average was collected earlier (end of May) and does not include the latest August research reports, so there is a deviation from the actual latest distribution. Institutional earnings forecasts diverge significantly: 2026E net profit attributable to shareholders range approximately RMB 1.349–1.507 billion (approximately ±5%), 2027E approximately RMB 1.633–1.928 billion. It should also be noted that the H-share (06821) earnings forecast table (etnet) only has 2 institutions, CLSA and Goldman Sachs, and was updated in February 2026, significantly lagging the latest A-share research reports, and should not be used as the current consensus.

3.3 Valuation Level and Institutional Ratings

Quote data as of the close on 2026-09-11: closing price RMB 164.13 (daily decline −3.66%), total market capitalization RMB 59.196 billion, tradable market capitalization RMB 52.205 billion, total share capital 361 million shares, tradable share capital 318 million shares. Valuation metrics: dynamic P/E ratio 56.87, dynamic P/B ratio 3.34 (stcn); cross-checked with Cailianshe/Baidu showing P/E (TTM) 57.16, P/E (static) 52.27, P/B ratio 3.34 (differences from TTM methodology and disclosure timing). 52-week range RMB 88.46–200.00 (Yahoo Finance), 1-year return +51.29% (Yahoo). Valuation background: as of 2026-03-30, the stock price was approximately RMB 100.70, corresponding to 2026E PE 24.1x (Kaiyuan Securities), meaning that after a significant rise over the past six months, the dynamic PE has been pushed up to approximately 57x (TTM). Correspondence with earnings forecasts (important): based on RMB 164.13 and total share capital of 361 million shares, corresponding to 2026E EPS of approximately RMB 4.18 → 2026E PE approximately 39x; corresponding to 2027E EPS of approximately RMB 5.15 → PE approximately 32x; corresponding to 2028E EPS of approximately RMB 6.41 → PE approximately 26x (based on Kaiyuan Securities forecasts); under institutional forward forecast methodology, 2026E PE is approximately in the 39–42x range. It can be seen that the "dynamic PE 57x" is TTM methodology (including the low profit base dragged down by H1 2026 exchange losses), and there is a clear difference from the forward forecast methodology, which must be noted when using. Target price ranges diverge greatly (recent RMB 193–235, early RMB 136–160), with differences mainly from valuation multiple assumptions (40x–50x 2026E PE) and report dates, with earlier target prices having lower reference value; the "target average price RMB 164.68" is a second-hand summary, single source (Baidu Stock Summary) and mixes research reports of different dates, could not be cross-verified, and is for reference only. Different quote sources (stcn/Cailianshe/Baidu/Yahoo) have inconsistent figures between 2026-09-09 and 09-11 due to stock price fluctuations (173.05→164.13); this note uniformly marks the 09-11 closing methodology.

4. Recent News and Announcements

4.1 H1 2026 Semi-Annual Report: Net Profit Declined Year-on-Year, Emerging Businesses and Orders Grew Rapidly

The company disclosed its H1 2026 semi-annual report on August 25, 2026. H1 2026 net profit attributable to shareholders of the listed company was approximately RMB 520.5 million, down 15.71% year-on-year; basic earnings per share RMB 1.45. Emerging business revenue was approximately RMB 1.304 billion, up 72.49% year-on-year; chemical macromolecule CDMO revenue was approximately RMB 736 million, up 94.14% year-on-year; chemical macromolecule business backlog grew 163.47% year-on-year. The company serves approximately 60 peptide drug projects, of which approximately 25 are weight-loss related. The formulation CDMO segment's backlog as of the semi-annual report disclosure date grew 30.93% year-on-year, of which overseas orders accounted for 33.37%. As of September 12, 2026, no new standalone annual earnings forecast or earnings flash report issued by the company in September was retrieved. The above business data are primarily from company disclosure methodology and have not been further verified against third-party statistical methodology.

4.2 2026 A-Share Restricted Stock Incentive Plan First Grant Implemented

The company disclosed and advanced its 2026 A-share restricted stock incentive plan on August 25–26, 2026. The plan intends to grant 3.388 million restricted shares, approximately 1.02% of the company's total A-share capital at the time of the draft plan announcement, of which the first grant is 2.711 million shares and the reserved grant is 677,000 shares. The first grant has 622 incentive recipients, with a first grant price of RMB 76.70/share, and the plan's maximum validity period is no more than 72 months. The stock sources include A-shares repurchased by the company from the secondary market and A-shares directionally issued to incentive recipients. The first grant portion has set assessment targets linked to operating revenue and net profit growth, with specific implementation subject to the assessment conditions in the company's final announcement.

4.3 Partial Shares from the 2025 Restricted Stock Incentive Plan Unlocked and Listed

The company disclosed on August 25, 2026 that the unlocking conditions for the first unlock period of the first grant portion of the 2025 A-share restricted stock incentive plan had been met. The relevant shares entered the listing and trading process around September 2026, and a third-party trading alert page shows that the estimated unlock quantity on September 7, 2026 was approximately 1.028 million shares, approximately 0.28% of total share capital. This quantity is estimated by a third party based on historical announcements, and the actual quantity should be subject to the company's official announcement and registration results. Unlocking is not equivalent to the relevant incentive recipients immediately reducing holdings.

4.4 Repurchase and Cancellation of Restricted Shares of Departed Incentive Recipients, 117,500 Shares Cancelled in August

Due to the departure of some incentive recipients, the company repurchased and cancelled shares not yet unlocked under the 2025 restricted stock incentive plan. Information disclosed on July 10, 2026 shows that involving 11 first grant incentive recipients and 4 reserved grant incentive recipients, a total of 117,500 A-share restricted shares were to be repurchased and cancelled, after which the company's total share capital is expected to change from 360,780,970 shares to 360,663,470 shares. According to the monthly share change report as of August 31, 2026, the company reduced A-share issued shares by 117,500 in August due to repurchase and cancellation, with repurchase prices of RMB 35.12/share and RMB 51.94/share respectively, and cancellation date of August 19, 2026. A third-party announcement summary shows the repurchase and cancellation amount was approximately RMB 4.32 million. This matter is not a large-scale share repurchase aimed at the secondary market.

4.5 Capital Increase of RMB 1.2397 Billion to Shanghai Asymchem Biotechnology Development Co., Ltd.

The company's H1 2026 semi-annual report disclosed that on August 20, 2026, the shareholders' meeting approved a related-party transaction to increase capital in Shanghai Asymchem Biotechnology Development Co., Ltd. The company, Suzhou Gaoling Qirui Healthcare Industry Investment Partnership (Limited Partnership), and Dr. HAO HONG intend to inject a total of RMB 1.2397 billion in cash to increase capital in the target company and subscribe to its newly registered capital. Currently available public information shows the matter has been approved by the shareholders' meeting. Existing search results could not fully verify the final equity structure and asset valuation details after the capital increase is completed; whether the transaction constitutes a major asset restructuring or leads to a change in control of the listed company is not indicated by existing information.

4.6 H1 2026 Earnings Briefing Held, No New Repurchase or M&A Plans Disclosed Yet

The company held its 2026 online earnings briefing through Panorama Network on September 3, 2026, addressing questions on ADC, peptide business capacity ramp-up, gross margin improvement, continuous production technology, formulation CDMO orders, and shareholder returns. The company stated it will prudently study financing methods based on development strategy, industry trends, and operating conditions, and will perform review and disclosure procedures in accordance with law if relevant plans arise. As of September 12, 2026, no new large-scale A-share repurchase plan, controlling shareholder increase plan, major reduction plan, or new major M&A matter announced by the company in September was found. The content of the earnings briefing is not equivalent to a formal board resolution or major matter announcement.

4.7 Shareholder Dynamics: No Major Changes in A-Share Controlling Shareholder or Actual Controller Found Yet

As of September 12, 2026, no change in Asymchem's controlling shareholder or actual controller was found, nor any new major reduction or increase plan published by A-share shareholders holding 5% or more. A third-party Hong Kong stock data page shows JPMorgan reduced approximately 82,300 shares on September 2, 2026, with the latest shareholding ratio at approximately 8.95%; this information comes from third-party compilation of Hong Kong stock interest change data, and no corresponding company A-share announcement or complete Hong Kong Stock Exchange original disclosure document was found in this search, so it is for reference only and cannot be directly deemed as A-share market shareholder dynamics.

4.8 Regulatory and Other Matters: No Major Penalty, Investigation, or Accident Announcements Found Yet

This search found no major regulatory events such as administrative penalties, formal investigations, exchange disciplinary actions, or regulatory inquiry letters against Asymchem in September 2026. Existing search results also found no announcements of major environmental penalties, drug quality accidents, major litigation, or production safety accidents involving the company from August to September 2026.

5. Stock Price Trend and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, Asymchem closed at RMB 164.13. Over the last 5 trading days, the stock price peaked at RMB 176.60 on September 8 and then declined continuously. The latest closing price is below MA5, MA10, and near MA20 levels, and is running below the Bollinger middle band. MACD is negative, RSI(14) approximately 41.30, indicating weak short-term momentum and relative strength; stochastic RSI approximately 10.66 suggests conditions for a technical rebound, but a rebound requires the price to reclaim short-term moving averages and be supported by volume. On the capital side, main-force capital was overall net outflow on September 11, but the final net outflow amount lacks cross-verifiable data. Recent turnover was approximately RMB 1.008–2.090 billion, average approximately RMB 1.357 billion, with current turnover approximately RMB 1.218 billion, without extreme volume-driven selling. The technical picture does not yet support a definitive directional judgment detached from key price levels and volume conditions.

5.3 Short-Term Outlook (Next Week, Scenario Projection, for Reference Only)

⚠️ Risk Warning: The following content is solely a subjective scenario projection based on closing data as of September 11, 2026 and public technical indicators. It does not constitute investment advice, nor a definitive prediction of future stock prices.

① Key Technical Levels

② Next Week Scenarios (Subjective Weights, Not Statistical Probabilities)

• Range-bound consolidation (relatively high weight, approximately 60%; this weight is a subjective heuristic judgment based on current technical patterns and capital flows, not a statistical probability): Price range approximately RMB 160–170. Trigger conditions are the stock price finding support near RMB 161–164, but the rebound unable to effectively break above RMB 169–170; turnover maintained in the recent normal range of approximately RMB 1.0–1.4 billion; no明显 strong catalyst in the pharmaceutical and CXO sectors. The corresponding implication is that short-term trading may repeatedly oscillate around RMB 161–170, waiting for capital to re-select direction
• Weaker downside (medium weight; a subjective heuristic judgment based on current technical patterns and capital flows, not a statistical probability): Price range approximately RMB 153–161. Trigger conditions are the closing price continuously breaking below RMB 161, with single-day turnover expanding to above RMB 1.5–1.8 billion, while main-force capital continues net outflow; or the pharmaceutical services and CXO sectors continue to underperform the broader market. If the RMB 154–158 area cannot provide effective support, short-term trading may move toward lower previous trading congestion zones; if the decline is accompanied by obvious volume expansion, it indicates that the degree of chip loosening may be higher than an ordinary technical pullback
• Rebound strengthening (low to medium weight; a subjective heuristic judgment based on current technical patterns and capital flows, not a statistical probability): Price range approximately RMB 170–178. Trigger conditions are the stock price first stabilizing in the RMB 161–164 area, then reclaiming RMB 169–170 with volume, and further breaking above RMB 174; single-day turnover continuously expanding to above RMB 1.5 billion, and main-force capital shifting from net outflow to continuous net inflow. If it breaks above RMB 176–178, the rebound strength may further increase. Since RSI is relatively weak and stochastic RSI is at a low level, conditions for a technical rebound exist, but only when the price reclaims MA10, MA20, and near the Bollinger middle band does the rebound become more confirmed

③ Capital and Liquidity Background

As of September 11, 2026, turnover over the last 5 trading days was approximately RMB 1.008–2.090 billion, average approximately RMB 1.357 billion; turnover rate approximately 2.33%, volume ratio approximately 0.94 to around 1, without showing extreme liquidity tightness. Shareholder structure data as of June 30, 2026, total number of shareholders approximately 51,700, top ten tradable shareholders holding approximately 196 million shares, accounting for approximately 56.72% of tradable shares; Tonghuashun statistics show institutional holdings totaling approximately 209 million shares, accounting for approximately 66.03% of tradable shares, of which fund holdings approximately 78.2804 million shares, accounting for approximately 24.38% of tradable shares, and other institutional holdings approximately 131 million shares, accounting for approximately 41.33% of tradable shares. Another Tonghuashun page shows 207 main-force institutions holding approximately 194.6 million shares, accounting for approximately 61.39% of tradable A-shares; the two pages differ due to different statistical methodologies. The notes only explicitly disclose fund and other institutional holdings, and do not explicitly state whether public funds, social security, or QFII are respectively among the top ten tradable shareholders, so further confirmation is not possible. The above shareholder data is more than two months from the September 11, 2026 close and cannot represent the real-time chip structure, which may have changed. At the trading level, Asymchem's recent turnover remains in the approximately RMB 1.0–2.0 billion range, with overall good liquidity, not a typical low-liquidity small-cap stock; however, institutional holding concentration is relatively high, and if institutional position adjustment or concentrated reduction occurs, periodic volatility may amplify.

Checkable volume confirmation signals: if single-day turnover continuously expands to above RMB 1.5 billion in the coming week and the stock price simultaneously reclaims the RMB 169–174 resistance zone, this can be regarded as a relatively strong confirmation signal of short-term capital re-entry; conversely, if turnover expands to above RMB 1.5 billion when breaking below RMB 161, attention should be paid to the risk of testing the RMB 154–158 support zone.

④ Points to Watch (Observation Ideas Only, Not Trading Instructions)

• Observe whether the RMB 161–164 area can stabilize with reduced volume; the above is only an observation idea, not a buy/sell instruction.
• Observe whether the RMB 169–174 area can be reclaimed with volume; the above is only an observation idea, not a buy/sell instruction.
• Observe whether the RMB 154–158 strong support zone is effectively broken; the above is only an observation idea, not a buy/sell instruction.
• Observe whether turnover can continuously reach above RMB 1.5 billion and improve in sync with main-force capital direction; the above is only an observation idea, not a buy/sell instruction.

The above scenario projection is based on September 11, 2026 closing data and historical price and technical indicator calculations. Short-term stock prices will also be disturbed by multiple factors such as news, capital flows, and the broader market environment. Technical indicators themselves have lag and limitations, do not constitute a guarantee of actual future trends, nor buy/sell advice. Please combine with the latest market information to make independent judgments and bear investment risks yourself.

6. Industry Landscape and Competitor Analysis

6.1 Industry Status

Asymchem's industry is pharmaceutical R&D outsourcing (CXO/CDMO), with downstream being global pharmaceutical companies and Biotech firms. Customer stickiness to CDMOs comes from the deep binding of processes, impurity profiles, cGMP registration documents, and customer filing materials. Once a commercial project is locked in, changing suppliers requires re-doing process validation and regulatory changes, so supplier stickiness for a single commercial project is strong; however, the company has no pricing power over drug selling prices, and quotes are essentially "cost-plus + technology premium" service pricing. Customers (especially MNC procurement departments) will still continuously pressure prices and demand cost reductions, and the company can only improve gross margin through process iteration and product structure upgrading. There is a significant gap between domestic and overseas gross margins (H1 2026 overseas 51.10% vs. domestic 24.67%).

6.2 Competitive Landscape

• Industry classification: Pharmaceuticals & Biotech → Medical Services → Medical R&D Outsourcing (CXO/CDMO); the company is positioned as a "one-stop CDMO integrated solutions provider," technology-driven (emphasizing the "D" = Development capability that distinguishes it from traditional CMO).
• The company covers chemical small-molecule drugs, TIDES, biologics, formulations, technology output, and synthetic biology, with the official website stating it "provides one-stop services across the full drug lifecycle to over 1,300 customers globally."
• Customer coverage: MNCs such as Merck, Pfizer, Bristol-Myers Squibb, AbbVie, Eli Lilly, as well as domestic innovative pharmaceutical companies such as Betta Pharmaceuticals, Hutchison MediPharma, Zai Lab, Fosun Pharma, and Dizal Pharma; historically, "cooperation has been established with 15 of the world's top 20 pharmaceutical companies, and 8 of them have been served continuously for over 10 years" (early annual report/prospectus methodology, not the latest 2025 methodology).
• Revenue structure migrating toward emerging businesses: FY2025 emerging business revenue RMB 1.929 billion, accounting for 28.92%, up 57.30% year-on-year; H1 2026 emerging business share has risen to approximately 36.16% (Eastmoney main business composition methodology, pending verification against the original semi-annual report).
• Emerging business segment FY2025 growth rates: chemical macromolecule CDMO RMB 1.028 billion, up 123.72% year-on-year; biological macromolecule CDMO RMB 294 million, up 95.76% year-on-year (overseas project revenue accounted for 39.55%); formulation CDMO RMB 284 million, up 18.44% year-on-year; clinical CRO RMB 282 million, up 26.53% year-on-year; synthetic biology and new technology output revenue not separately disclosed in the annual report.
• Customer type structure: FY2025 large pharmaceutical company revenue RMB 2.916 billion (up 8.36% year-on-year), small and medium pharmaceutical company revenue RMB 3.755 billion (up 20.57% year-on-year, with small and medium customers accounting for more than half); overseas customer revenue RMB 4.921 billion (up 14.85% year-on-year), domestic customer revenue RMB 1.749 billion (up 15.09% year-on-year).
• The research notes did not provide specific names, revenue scale, market share, or comparison data of peer competitors, so a quantitative description of the comparable company competitive landscape cannot be given in this section.

6.3 Main Competitors

The scope of the research notes only covers Asymchem's own company overview, main business, and industry chain upstream/downstream position, and does not include any peer comparable company names, revenue scale, gross margin, or market share data, so substantive peer comparison cannot be conducted. As for the company itself, its differentiated positioning is "one-stop CDMO integrated solutions provider," technology-driven (emphasizing "D" = Development capability), with product structure migrating from small-molecule CDMO (FY2025 70.98%, gross margin 46.83%) to emerging businesses (FY2025 28.92%, up 57.30% year-on-year), and H1 2026 emerging business share has risen to approximately 36.16% (Eastmoney main business composition methodology, pending verification against the original semi-annual report). Peer benchmarking data is missing; it is recommended to supplement comparable CDMO companies' revenue, gross margin, and emerging business share methodology before comparison.

7. Risk Warnings

• Exchange rate fluctuations may continue to suppress net profit attributable to shareholders. The company's overseas revenue accounted for 66.59% in H1 2026, with exchange losses of approximately RMB 200 million in the reporting period, significantly higher than approximately RMB 31 million in the same period last year; even if the main business maintains growth, exchange rate changes may still cause significant fluctuations in profit and earnings per share.
• Traditional small-molecule CDMO faces revenue pressure risk. H1 2026 small-molecule CDMO revenue was RMB 2.297 billion, down 5.44% year-on-year, while this business still accounted for 63.68% of revenue; if clinical or commercial project delivery pace falls short of expectations, it may affect overall revenue stability.
• Uncertainty in converting high growth of emerging businesses into profit. H1 2026 emerging business revenue grew 72.49% year-on-year, but 2025 emerging business gross margin was 30.12%, significantly lower than the 46.83% of small-molecule CDMO; peptides, biological macromolecules, and other businesses are still in expansion and capacity ramp-up stages, and may face risks of scale release falling short of expectations or profitability below expectations.
• Order growth is not equivalent to current-period revenue recognition. The company's backlog as of the disclosure date was USD 1.673 billion, up 53.77% year-on-year, but order fulfillment is still affected by customer R&D progress, project approval, production delivery, and commercialization pace; if the order conversion cycle lengthens, it may cause revenue guidance and institutional earnings forecasts to fall short.
• Customer and regional structure may bring bargaining and concentration risks. The top five customers in 2025 accounted for approximately 35.87% of combined sales, a figure not yet cross-verified against the original annual report; the company's overseas revenue and MNC project gross margins are relatively high, but customer procurement departments may still continuously pressure prices, and domestic business gross margins are relatively low, so changes in customer structure may affect comprehensive gross margin.
• Valuation pullback risk is relatively prominent. As of September 11, 2026, the company's dynamic P/E ratio was approximately 56.6–56.9x, with the stock price down approximately 17.94% from the 52-week high; if emerging business growth, order fulfillment, or profit recovery fall short of market expectations, the relatively high valuation may amplify stock price volatility.
• Short-term technical and capital flow weakness. The stock price is already below MA10, MA20, and the Bollinger middle band, MACD is negative, and main-force capital was overall net outflow on September 11; if support near RMB 161 is lost and turnover expands significantly, the technical picture may further seek support in the RMB 154–158 area.
• The company's capital increase to Shanghai Asymchem Biotechnology Development Co., Ltd. involves a total cash amount of RMB 1.2397 billion, and public information has not yet fully verified the final equity structure and asset valuation details after the capital increase is completed; capital investment, related-party transaction execution, and subsequent returns from related businesses still require continuous attention.

8. Conclusion and Outlook

Asymchem's medium-term growth logic mainly comes from emerging business expansion and improved order reserves. Businesses such as peptides, oligonucleotides, biological macromolecules, formulations, and clinical CRO continue to scale up, chemical macromolecule business backlog grew 163.47% year-on-year, and emerging businesses became the core source of revenue growth in H1 2026. If the backlog can be converted as planned and capacity ramp-up and process optimization proceed smoothly, the company's revenue is expected to grow along the full-year guidance of 19%–22%.

On the profit side, both operating profit and exchange rate factors need to be observed simultaneously. H1 2026 comprehensive gross margin was 42.27%, up 0.31 percentage points year-on-year at constant currency, and adjusted net profit maintained growth, indicating that the main business still has resilience; however, the decline in net profit attributable to shareholders and the relatively high proportion of overseas revenue make the impact of exchange rate fluctuations on reported profit relatively significant. In addition, although the rising share of emerging businesses is conducive to opening up growth space, their current gross margin is lower than that of small-molecule CDMO, and changes in revenue structure may not immediately translate proportionally into profit growth.

Valuation and trading levels have already reflected relatively high growth expectations. Based on the current price, the forward P/E ratios for 2026E, 2027E, and 2028E based on institutional forecasts are approximately 39x, 32x, and 26x, but institutional forecasts are not company commitments, and the current technical picture is in a short-term adjustment state. Going forward, key focus should be on order fulfillment, revenue guidance completion, exchange gain/loss changes, emerging business gross margin, and whether the stock price can reclaim the RMB 169–174 area.

Data Sources

• Asymchem (002821.SZ) Business Analysis-PC_HSF10 Data
• SZ.002821 Asymchem ASYMCHEM LABS - A-share Real-time Quote - Company Information
• Asymchem (sz002821)
• China Securities Journal - Asymchem Laboratories (Tianjin) Co., Ltd. - | Page B088: Information Disclosure | Previous Next
• Asymchem (002821.SZ) Core Themes-PC_HSF10 Data - Core Themes
• Asymchem Laboratories (Tianjin) Co., Ltd. - Top
• Asymchem (002821) - Asymchem (002821)
• Asymchem (002821)_Stock Overview_Stock Price_Real-time Quotes_Chart_News_Commentary_Financial Reports_FinScope-AI Makes Investing Simpler
• Asymchem: 2025 Annual Report - Securities Star - -1,999,894.83 -152,656.70 -1,634,462.61
• Nanyang Commercial Bank
• Asymchem: Domestic Simultaneous Disclosure Announcement _ Asymchem (002821) _ Announcement Text
• Asymchem: H-share Announcement: Monthly Return of Equity Issuer _ Asymchem (002821) _ Announcement Text
• Shenzhen Market Marginable Securities List (20260508) - Shenzhen A | 002805 | Fengyuan Shares | 0 | Main Board B
• Asymchem: 164.13 -3.66% -6.23 002821 Sohu Securities
• Asymchem (002821)
• Asymchem Laboratories (Tianjin) Co., Ltd.: Official Announcements - Stock Market News
• Asymchem Laboratories (Tianjin) (SHE:002821) Statistics & Valuation Metrics
• Asymchem (002821) Quote Data_Chart_Jiufang Zhitou
• Margin Trading Transaction Details - Quote Center
• Asymchem 2025 Revenue RMB 6.670 Billion, Net Profit Up Nearly 20%
• Asymchem 2025 Revenue RMB 6.670 Billion, Net Profit Up Nearly 20% | HK & US Stock Information | Huashengtong
• Asymchem Laboratories Official Website - Corporate News
• Asymchem (002821) Main Business Operating Analysis Query | Chagu.com - gubit.cn - Gubit.China
• Asymchem: Net Profit of RMB 1.133 Billion in 2025, Over 300 New Customers Added During the Year
• Asymchem 2025 Revenue RMB 6.670 Billion, Net Profit Up Nearly 20%
• Asymchem: Net Profit of RMB 1.133 Billion in 2025, Over 300 New Customers Added During the Year - Asymchem: Net Profit of RMB 1.133 Billion in 2025, Over 300 New Customers Added During the Year
• Asymchem: 2025 Annual Report - Annual Report - Periodic Financial Reports - Huibo Research Information - Asymchem: 2025 Annual Report
• Shanghai-Shenzhen Company Announcement Titles - Asymchem: 2025 Financial Final Accounts Report - March 31, 2026 - Tonghuashun
• Asymchem: 2025 Annual Report, 2025 Annual Report Summary, 2025 Annual Audit Report - Annual Report - Periodic Financial Reports - Huibo Research Information - Asymchem: 2025 Annual Report, 2025 Annual Report Summary, 2025 Annual Audit Report
• Asymchem Financial Report Summary
• 06821.HK Asymchem | ASYMCHEM | Company Information - Financial Ratio Overview - 06821 Asymchem